Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

AS-i Harju Elekter Group majandustulemused, 1-6/2026

View original at globenewswire.com
“Ärikasum enne kulumit (EBITDA) 2 266 4 658 -51,4% 3 905 8 523 -54,2%”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q2 and H1 2026 results fell significantly short of both revenue and profit targets due to lower-than-expected sales volume and part of revenue shifting to future periods

    60% confidence
  • In Sweden, long-execution-time projects make up a significant share of the order book, with realization extending into 2028

    60% confidence
  • Ongoing preparations and a growing order book create the conditions for servicing larger project volumes and for revenue and profitability growth in future years

    60% confidence
  • 2026 is considered a transition year during which the company prepares for the next high-activity periods, with a stronger order book for H2 than H1

    60% confidence
  • The Estonian local distribution grid operator has reduced its investment volumes, weighing on the local market

    60% confidence

Data points we hold from this source

Harju Elekter Group · net income0.272 USD
Harju Elekter Group · labor costs21.4 USD
Harju Elekter Group · margin12.2 percent
Harju Elekter Group · long term financial investments27.223 USD
Harju Elekter Group · labor cost ratio27.7 percent
Harju Elekter Group · capital expenditure3.9 USD
Harju Elekter Group · admin expenses5.627 USD
Harju Elekter Group · admin expense ratio7.3 percent
Harju Elekter Group · employee wage costs16.7 USD
Harju Elekter Group · ebit margin2.6 percent
Harju Elekter Group · debt35.467 USD
Harju Elekter Group · inventory20.456 USD
Harju Elekter Group · equity95.155 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
AS-i Harju Elekter Group majandustulemused, 1-6/2026 — Source | Via News | ViaNews Market